Secukinumab
未知生产厂商
Secukinumab is an immunomodulating agent and interleukin antagonist used to manage plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, along with other joint inflammatory disorders.
Secukinumab is an immunomodulating agent and interleukin antagonist used to manage plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, along with other joint inflammatory disorders.
Interleukin-17 (IL-17) is a family of proinflammatory cytokines that mediate normal inflammatory and immune responses. The production of IL-17 is mostly promoted by T cells, such as T-helper-17 (Th17) cells, but can also be caused by mast cells and neutrophils. IL-17 binds to IL-17 receptors, which are expressed on various cell types, including keratinocytes. IL-17 signalling pathway promotes angiogenesis and the release of proinflammatory cytokines, chemokines, and mediators of tissue damage. IL-17A is a member of IL-17 with the most prominent role in host defence and autoimmunity. IL-17A is often upregulated in several autoimmune disorders, such as psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis, making it an important therapeutic target. IL-17A is also more potent than IL-17F, another member of IL-17, with a much greater affinity to the IL-17 receptor. Secukinumab selectively binds to and inhibits IL-17A, preventing its interaction with the IL-17 receptor and activation of the IL-17 receptor signalling pathway associated with inflammatory processes.
Secukinumab is indicated the treatment of moderate to severe plaque psoriasis in patients six years and older who are candidates for systemic therapy or phototherapy. In Europe, the drug is used in children and adolescents six to 18 years of age for this indication. It is also indicated for the treatment of active psoriatic arthritis (PsA). In the US, it is approved for patients two years of age and older while in Europe, it is used alone or in combination with methotrexate in patients six years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. Secukinumab is also indicated in the treatment of active enthesitis-related arthritis (ERA). In the US, it is approved for patients four year of age and older. In Europe, it is used alone or in combination with methotrexate in patients six years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. In the US, secukinumab is indicated for the treatment of adults with active ankylosing spondylitis or non-radiographic axial spondyloarthritis with objective signs of inflammation.
共 8 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
